US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% NVDA $233.95 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% TSLA $370.59 ▲+0.00%
FinancialContent

Articles published by Almirall S.A.

News headline image
AAD 2026: Almirall Presents New Clinical and Real‑world Evidence Across Atopic Dermatitis, Psoriasis, Actinic Keratosis and Acne
From Almirall S.A.
Via Business Wire
News headline image
Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
From Almirall S.A.
Via Business Wire
News headline image
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
From Almirall S.A.
Via Business Wire
News headline image
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
From Almirall S.A.
Via Business Wire
Tickers ABSI
News headline image
Almirall’s Nine-month 2023 Results:
From Almirall S.A.
Via Business Wire
News headline image
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
From Almirall S.A.
Via Business Wire